The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
_256_384.jpg)
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
